Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Aura Biosciences, Inc.NASDAQ: AURA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of $300K rose 212.5% year over year, behind the +5279.6% change in trailing-twelve-month financing cash flow. Sequentially, it fell 89.2% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +212.5% toward the trailing-twelve-month pace of +5279.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 77.16M USD
- Year-over-year change
- +4737.3%
- 4-year CAGR
- -17.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 77.16M | +4737.3% |
| FY2024 | 2024-12-31 | 1.6M | -98.4% |
| FY2023 | 2023-12-31 | 97.29M | +1.7% |
| FY2022 | 2022-12-31 | 95.63M | -42.5% |
| FY2021 | 2021-12-31 | 166.26M | — |
Financing Cash Flow vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5279.6% is the 3rd highest of 11, against a peer median of +17.3%.
- Over three fiscal years its annual growth of -6.9% compares with a peer median of +128.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $436.09M USD | +91.6% | +2614.9% | — | |
| LTM Mar 2026 | $171.98M USD | +5.5% | — | 2258.5% | |
| LTM Mar 2026 | CHF 105.86M CHF | -32.9% | +370.6% | 21003.4% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $94.38M USD | +72496.9% | +9.1% | 1320.9% |
| LTM Mar 2026 | $77.43M USD | +29.1% | — | — | |
| LTM Mar 2026 | $77.36M USD | +5279.6% | -6.9% | — | |
| LTM Mar 2026 | $69.59M USD | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $53.56M USD | -16.0% | -33.7% | 1199.5% | |
| LTM Mar 2026 | $47.24M USD | +93.8% | -8.9% | 14179.4% | |
| FY2025 | $1.21M USD | -100.7% | — | 18.7% | |
| LTM Mar 2026 | $143.84K USD | -100.0% | — | 0.2% | |
| Peer median (excluding AURA) | — | +17.3% | +128.2% | 1260.2% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| Deferred Income Tax | 14K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.31M | 6.41M | 8.77M | 11.72M | 14.32M |
| Change in Working Capital | (315K) | (3.1M) | 4.44M | (2.64M) | 5.97M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.05M | 340K | (1.04M) | 482K | (846K) |
| Other Working Capital | (1.37M) | (3.44M) | 5.48M | (3.12M) | 6.82M |
| Other Non-Cash Items | 4K | (325K) | (1.95M) | (3.19M) | 32K |
| Operating Cash Flow | (32.41M) | (54.6M) | (63.85M) | (79.81M) | (84.74M) |
| Capital Expenditures | (2.13M) | (1.09M) | (709K) | (1.25M) | (447K) |
| Acquisitions (Net) | 0 | 66.78K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (119.78M) | (233.65M) | (59.11M) | (83.96M) |
| Sales of Investments | 0 | 53.01M | 120.4M | 129.18M | 120M |
| Other Investing Activities | 0 | (66.78K) | 0 | 0 | 0 |
| Investing Cash Flow | (2.13M) | (67.87M) | (113.96M) | 68.82M | 35.6M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 78.7M | 8.55M | 3.17M | 1.6M | 77.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 334K | 430K | 1.5M | 0 | 0 |
| Financing Cash Flow | 166.26M | 95.63M | 97.29M | 1.6M | 77.16M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (186K) |
| Net Change in Cash | 131.72M | (26.84M) | (80.52M) | (9.39M) | 27.82M |
| Free Cash Flow | (34.54M) | (55.7M) | (64.56M) | (81.06M) | (85.19M) |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.